Overview

A Bioequivalence Study Of 4 Mg Fesoterodine Extended-Release Tablets (Toviaz™) In Healthy Subjects

Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
To demonstrate bioequivalence of fesoterodine 4 mg tablets manufactured at Vega Baja, versus Zwickau.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Treatments:
Fesoterodine